slides · global inventory
Image
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 119,566
Current window 87,061-87,090
Pages 3,986
Rows per page 30
Component
87,061-87,090 of 119,566
05
Uses a visual comparison between small molecule and biologic data availability to frame the problem.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
06
The slide uses a process flow to explain the technical solution.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a metaphor to frame the company's value proposition against the backdrop of low clinical trial success rates.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
09
The diagram represents a flywheel or iterative process loop.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
11
The 'o' in 'zero-shot' is replaced by a molecular/network graphic.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
14
The slide highlights the efficacy of the de novo design model by showing a histogram of binding affinities and key performance metrics.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
17
The slide highlights the 'zero-shot' nature of the model, emphasizing the lack of lead optimization and the successful application across four distinct therapeutic targets.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
21
Uses a Venn diagram to represent the intersection of three properties optimized by AI.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
22
The slide uses a visual comparison between a small sampled space (50k) and a massive hypothetical space (7x10^6) to illustrate the efficiency of the AI approach.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
27
Uses a tripartite structure to show application areas for multi-valent binding.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
29
The letter 'o' in 'potential' is replaced by the company's circular logo graphic.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
30
Includes a biological diagram of TLS and a Kaplan-Meier survival curve.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
35
The slide explains the mechanism of incorporating nsAA into mAbs to create ADC precursors.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
37
The slide uses a series of diagrams to illustrate the biological engineering features of the cell line.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
38
The slide uses a bar chart to show that even with 3 nsAA sites, the relative expression remains comparable to wild-type, validating the platform's efficiency.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
39
The slide uses a mass spectrometry plot to show the shift in molecular mass after conjugation, highlighting the precision of the Absci platform.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
43
Absci | Investor Presentation Deck | 48 slidesAbsci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
02
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Setup1 hit
03
The slide details a corporate M&A event and associated private placement financing.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Setup1 hit
05
The slide uses a pipeline table format to show the progression of various drug candidates (SPY001-SPY230) across discovery, IND-enabling, and clinical stages.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Golden Circle1 hit
09
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
10
The chart compares Cyno Half-Life vs Human Half-Life, showing YTE mAbs outperforming WT mAbs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
18
The slide uses a central antibody diagram to annotate specific technical improvements over 1st generation mAbs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
19
Includes structural biology visualization and dose-response curves for two different adhesion targets.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
26
The slide uses a standard 2x2 grid for program summary and a simple timeline for catalysts.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
33
The slide uses a Y-shaped antibody diagram to annotate specific technical improvements.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
07
The slide emphasizes the multi-device (desktop/mobile) nature of the product and its role as a central hub for seller operations.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a process-oriented arrow graphic to map app features to user benefits.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Beat · Solution1 hit
20
The slide uses a sports metaphor for success.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations 1 hit
21
Vivid Seats | Investor Presentation Deck | 24 slidesVivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations 1 hit